Heart Attack News and Research

RSS

Interleukin Genetics reports 166% increase in overall genetic test revenue for first-quarter 2010

Interleukin Genetics, Inc. announced today financial and operational results for the first quarter ended March 31, 2010.

14 May 2010

RegeneRx Biopharmaceuticals awarded $3M federal grant to develop heart attack drug

RegeneRx Biopharmaceuticals, Inc. announced today that it has been awarded a $3 million grant from the National Institutes of Health's National Heart, Lung and Blood Institute to support and accelerate the clinical development of its novel product candidate RGN-352, an injectable formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4, for patients who have suffered an acute myocardial infarction, or AMI, commonly known as a heart attack.

14 May 2010

GE Healthymagination Fund invests $5M in CardioDx

GE Healthcare, the healthcare business of GE and CardioDx, a pioneer in cardiovascular genomic diagnostics, announced today that the companies have entered into a strategic alliance to advance and co-develop diagnostic technologies to improve the care and management of patients with cardiovascular disease.

14 May 2010

Stereotaxis to be featured prominently in 31st HRS

Stereotaxis' safety and efficacy in the treatment of patients with complex arrhythmias such as atrial fibrillation, ventricular tachycardia, and congenital heart defects will be featured prominently in the scientific program of the 31st Annual Heart Rhythm Scientific Sessions in Denver, Colorado. Eight podium presentations and eight posters will underscore the broad clinical leadership that Stereotaxis has achieved in the treatment of patients with complex cardiac arrhythmias.

13 May 2010

Individual's lifestyle choices can affect cholesterol, triglycerides levels: Mayo Clinic Health Letter

Diet and lifestyle choices aren't only evident on the bathroom scale. The effect of these choices is also reflected with relative accuracy in cholesterol numbers.

13 May 2010

Resverlogix' Phase 2 ASSERT trial dosing complete ahead of schedule

Resverlogix is pleased to announce that the Phase 2 ASSERT clinical trial for its lead drug, RVX-208, a small molecule therapy for the treatment of atherosclerosis has now completed dosing. "The completion of dosing for our Phase 2 ASSERT trial, five months ahead of schedule and without any alterations to the dose levels of the three drug receiving cohorts, is another major step forward in the development of this important cardiovascular drug.

13 May 2010

CHD mortality rate in Ontario decreased by 35%: Study

From 1994 to 2005 in Ontario, Canada, there was a 35 percent decrease in the rate of deaths from coronary heart disease, with about half of this reduction associated with improvements in traditional CHD risk factors such as total cholesterol levels and systolic blood pressure, according to a study in the May 12 issue of JAMA.

12 May 2010

First Edition: May 11, 2010

Today's coverage includes more details regarding how the new health law moves forward with efforts to provide health insurance coverage to young adults.

11 May 2010

Positive results from Cytori's Celution-based ADRC trial for treatment of no-option chronic heart disease patients

The first clinical trial of adipose (fat) tissue-derived stem and regenerative cells (ADRCs) for the treatment of no-option chronic heart disease patients showed the following: the procedure was safe and feasible; it demonstrated a statistically significant improvement in maximum oxygen consumption and patients' aerobic capacity measured as metabolic equivalents

10 May 2010

Zilver PTX Drug-Eluting Peripheral Stent safe and effective for treating SFA lesions

Patients treated with the Zilver® PTX™ Drug-Eluting Peripheral Stent maintained clinical improvement at two years, according to interim results from the Zilver® PTX™ Global Registry presented today as a late-breaking clinical trial at the Society for Cardiovascular Angiography and Interventions (SCAI) 33rd Annual Scientific Sessions.

10 May 2010

Everolimus-eluting stents more effective than paclitaxel-eluting stents

Results from the SPIRIT IV clinical trial, which were first presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2009 scientific symposium, were published today in the New England Journal of Medicine.

10 May 2010

Novel imaging techniques improve post heart attack survival rates in mouse model

Human adult stem cells injected around the damage caused by a heart attack survived in the heart and improved its pumping efficiency for a year in a mouse model, researchers at The University of Texas MD Anderson Cancer Center report online ahead of publication in Circulation Research.

10 May 2010

Guardian, MHA collaborate to raise awareness about depression, disability

In the face of historically high unemployment, record home foreclosures and a volatile economy, The Guardian Life Insurance Company of America, an industry leader in group and individual disability insurance, is collaborating with Mental Health America in a groundbreaking effort to raise awareness about depression as a common cause of disability.

7 May 2010

Cytori Therapeutics to initiate European medical device approval study for Celution System

The first clinical trial of adipose (fat) tissue-derived stem and regenerative cells for the treatment of heart attacks showed a substantial reduction in the size of injury to the heart, an improvement in the amount of blood supply to the heart muscle, and a corresponding functional improvement in the amount of blood the heart can pump.

7 May 2010

Advances in combination adult stem cell treatment for acute myocardial infarction presented at SCAI

This week, TCA Cellular Therapy's Medical Director Gabriel Lasala, M.D. presents advances in a proprietary combination adult stem cell treatment for acute myocardial infarction at the Society for Cardiovascular Angiography and Interventions (SCAI) scientific conference in San Diego.

7 May 2010

THI at St. Luke's reveals new insights on how adult stem cells repair damaged hearts following heart attack

Physician scientists at the Texas Heart Institute at St. Luke's Episcopal Hospital (THI at St. Luke's) are publishing research this week that reveals new insights into how a particular set of human adult stem cells helps repair damaged hearts following a heart attack in laboratory mice.

7 May 2010

Swedish researchers present a new principle for inhibiting atherosclerosis

7 May 2010

Research reveals reason for ineffectiveness of antioxidants against cardiovascular disease

A new study by researchers at the Swedish medical university Karolinska Institutet shows that the immune defence's T cells can attack the "bad" LDL cholesterol and thereby cause an inflammation that leads to atherosclerosis. By producing a vaccine against the T cell receptors, the researchers have managed to inhibit the development of atherosclerosis in animals.

6 May 2010

Abbott's SPIRIT IV trial results published in The New England Journal of Medicine

Findings from Abbott's SPIRIT IV trial, one of the largest randomized clinical trials comparing two drug eluting stents, with 3,690 U.S.-based patients, were published today in The New England Journal of Medicine.

6 May 2010

Forbidding ambulance costs deter heart attack victims from calling ‘000’: National Heart Foundation

According to a new survey conducted by The National Heart Foundation, the forbidding ambulance costs are preventing timely calls to the emergency by at least one in 10 heart attack victims. The Foundation also released a discussion paper released during Heart Week urging free universal ambulance services in all states and territories. Dr Bill Coote in the paper entitled Universal Ambulance Cover has also said that this would prevent many heart attack deaths.

5 May 2010

Heart Attack News and Research

Interleukin Genetics reports 166% increase in overall genetic test revenue for first-quarter 2010

RegeneRx Biopharmaceuticals awarded $3M federal grant to develop heart attack drug

GE Healthymagination Fund invests $5M in CardioDx

Stereotaxis to be featured prominently in 31st HRS

Individual's lifestyle choices can affect cholesterol, triglycerides levels: Mayo Clinic Health Letter

Resverlogix' Phase 2 ASSERT trial dosing complete ahead of schedule

CHD mortality rate in Ontario decreased by 35%: Study

First Edition: May 11, 2010

Positive results from Cytori's Celution-based ADRC trial for treatment of no-option chronic heart disease patients

Zilver PTX Drug-Eluting Peripheral Stent safe and effective for treating SFA lesions

Everolimus-eluting stents more effective than paclitaxel-eluting stents

Novel imaging techniques improve post heart attack survival rates in mouse model

Guardian, MHA collaborate to raise awareness about depression, disability

Cytori Therapeutics to initiate European medical device approval study for Celution System

Advances in combination adult stem cell treatment for acute myocardial infarction presented at SCAI

THI at St. Luke's reveals new insights on how adult stem cells repair damaged hearts following heart attack

Swedish researchers present a new principle for inhibiting atherosclerosis

Research reveals reason for ineffectiveness of antioxidants against cardiovascular disease

Abbott's SPIRIT IV trial results published in The New England Journal of Medicine

Forbidding ambulance costs deter heart attack victims from calling ‘000’: National Heart Foundation

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News